Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Diseases of the Digestive System - Liver
What is the purpose of this trial?
A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
- Ages18 - 75 years
- Trial withCymaBay Therapeutics, Inc.
- Start Date12/12/2018
- End Date12/30/2020
- Last Updated12/21/2018
- Study HIC#2000024082